AR099856A1 - Métodos para diagnosticar y tratar la enfermedad de intestino inflamado - Google Patents
Métodos para diagnosticar y tratar la enfermedad de intestino inflamadoInfo
- Publication number
- AR099856A1 AR099856A1 ARP150100901A ARP150100901A AR099856A1 AR 099856 A1 AR099856 A1 AR 099856A1 AR P150100901 A ARP150100901 A AR P150100901A AR P150100901 A ARP150100901 A AR P150100901A AR 099856 A1 AR099856 A1 AR 099856A1
- Authority
- AR
- Argentina
- Prior art keywords
- level
- measured
- patient
- hepg
- mrna expression
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 208000028774 intestinal disease Diseases 0.000 title 1
- 108020004999 messenger RNA Proteins 0.000 abstract 9
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 abstract 4
- 238000002560 therapeutic procedure Methods 0.000 abstract 4
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 abstract 3
- -1 CCL4 Proteins 0.000 abstract 3
- 102100023073 Calcium-activated potassium channel subunit alpha-1 Human genes 0.000 abstract 3
- 102100030614 Carboxypeptidase A2 Human genes 0.000 abstract 3
- 108010070357 D-Aspartate Oxidase Proteins 0.000 abstract 3
- 102100039462 D-aspartate oxidase Human genes 0.000 abstract 3
- 102100040515 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Human genes 0.000 abstract 3
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 abstract 3
- 108010008599 Forkhead Box Protein M1 Proteins 0.000 abstract 3
- 102000007237 Forkhead Box Protein M1 Human genes 0.000 abstract 3
- 102100023416 G-protein coupled receptor 15 Human genes 0.000 abstract 3
- 102100030386 Granzyme A Human genes 0.000 abstract 3
- 102100030385 Granzyme B Human genes 0.000 abstract 3
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 abstract 3
- 101001049859 Homo sapiens Calcium-activated potassium channel subunit alpha-1 Proteins 0.000 abstract 3
- 101000966982 Homo sapiens Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Proteins 0.000 abstract 3
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 abstract 3
- 101000829794 Homo sapiens G-protein coupled receptor 15 Proteins 0.000 abstract 3
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 abstract 3
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 abstract 3
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 abstract 3
- 101000961382 Homo sapiens Mitochondrial calcium uniporter regulator 1 Proteins 0.000 abstract 3
- 101000957340 Homo sapiens Multivesicular body subunit 12B Proteins 0.000 abstract 3
- 101001071238 Homo sapiens PHD finger protein 14 Proteins 0.000 abstract 3
- 101000651291 Homo sapiens TRAF-interacting protein with FHA domain-containing protein B Proteins 0.000 abstract 3
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 abstract 3
- 101000787917 Homo sapiens Transmembrane protein 200A Proteins 0.000 abstract 3
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 abstract 3
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 abstract 3
- 102100039374 Mitochondrial calcium uniporter regulator 1 Human genes 0.000 abstract 3
- 108091006675 Monovalent cation:proton antiporter-2 Proteins 0.000 abstract 3
- 102100038748 Multivesicular body subunit 12B Human genes 0.000 abstract 3
- 102100036866 PHD finger protein 14 Human genes 0.000 abstract 3
- 102100027653 TRAF-interacting protein with FHA domain-containing protein B Human genes 0.000 abstract 3
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 abstract 3
- 102100025940 Transmembrane protein 200A Human genes 0.000 abstract 3
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 3
- 102000006495 integrins Human genes 0.000 abstract 3
- 108010044426 integrins Proteins 0.000 abstract 3
- 239000000523 sample Substances 0.000 abstract 3
- 108091006255 SLC8A3 Proteins 0.000 abstract 2
- 102100032576 Sodium/calcium exchanger 3 Human genes 0.000 abstract 2
- 239000012472 biological sample Substances 0.000 abstract 2
- 229940123038 Integrin antagonist Drugs 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 239000013610 patient sample Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461971379P | 2014-03-27 | 2014-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099856A1 true AR099856A1 (es) | 2016-08-24 |
Family
ID=54196399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100901A AR099856A1 (es) | 2014-03-27 | 2015-03-26 | Métodos para diagnosticar y tratar la enfermedad de intestino inflamado |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10273542B2 (enExample) |
| EP (1) | EP3122377A4 (enExample) |
| JP (3) | JP7054990B2 (enExample) |
| KR (2) | KR20220065091A (enExample) |
| CN (2) | CN106102767B (enExample) |
| AR (1) | AR099856A1 (enExample) |
| AU (3) | AU2015235986B2 (enExample) |
| BR (1) | BR112016020053A2 (enExample) |
| CA (1) | CA2939246A1 (enExample) |
| IL (2) | IL247266B (enExample) |
| MA (1) | MA39804A (enExample) |
| MX (2) | MX2016012282A (enExample) |
| RU (1) | RU2016136716A (enExample) |
| SG (1) | SG11201607938UA (enExample) |
| WO (1) | WO2015148809A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0908665A2 (pt) * | 2008-05-16 | 2020-08-18 | Genentech Inc | método para a determinação da eficácia de um antagonista de integrina beta7 para o tratamento de um distúrbio inflamatório gastrointestinal, método de predição da responsividade de um paciente, método para a determinaçao da dosagem de um antagonista de integrina beta7, método para determinaçao do regime terapêutico de um antagonista de integrina beta7, método para predição de prognóstico de uma doença inflamatória intestinal, método de elaboração de um tratamento e método de identificação de uma população de linfócitos |
| CN106102767B (zh) | 2014-03-27 | 2021-08-10 | 豪夫迈·罗氏有限公司 | 用于诊断和治疗炎症性肠病的方法 |
| EP3262072A1 (en) * | 2015-02-26 | 2018-01-03 | F. Hoffmann-La Roche AG | Integrin beta7 antagonists and methods of treating crohn's disease |
| GB201611738D0 (en) * | 2016-07-05 | 2016-08-17 | Cambridge Entpr Ltd | Biomarkers for inflammatory bowel disease |
| CN107083423B (zh) * | 2017-03-27 | 2022-01-28 | 北京极客基因科技有限公司 | 一种药物靶点预测和药物全方面评价方法 |
| WO2019200202A1 (en) | 2018-04-12 | 2019-10-17 | Morphic Therapeutic, Inc. | Antagonists of human integrin (alpha4)(beta7) |
| US20220364171A1 (en) * | 2018-11-23 | 2022-11-17 | Katholieke Universiteit Leuven | Predicting a treatment response in inflammatory bowel disease |
| JP2022523564A (ja) | 2019-03-04 | 2022-04-25 | アイオーカレンツ， インコーポレイテッド | 機械学習を使用するデータ圧縮および通信 |
| KR20220088529A (ko) | 2019-05-14 | 2022-06-27 | 프로메테우스 바이오사이언시즈, 인크. | Tl1a 환자 선택 방법, 시스템 및 장치 |
| JP2022541125A (ja) | 2019-06-27 | 2022-09-22 | サイファー メディシン コーポレーション | 患者を層別化するための分類子の開発 |
| TWI775182B (zh) | 2019-10-16 | 2022-08-21 | 美商莫菲克醫療股份有限公司 | 抑制人類整合素αβ |
| US12394524B2 (en) * | 2020-07-22 | 2025-08-19 | Iterative Scopes, Inc. | Systems and methods for analysis of medical images for scoring of inflammatory bowel disease |
| JP2023536158A (ja) | 2020-07-31 | 2023-08-23 | ジェネンテック， インコーポレイテッド | 抗インテグリンβ７抗体製剤及び装置 |
| KR20240018404A (ko) * | 2020-09-01 | 2024-02-13 | 사이퍼 메디슨 코퍼레이션 | 항-tnf 요법에 대한 반응을 예측하기 위한 방법 및 시스템 |
| WO2023061502A1 (zh) * | 2021-10-15 | 2023-04-20 | 苏州生物医药转化工程中心 | 一种双特异性结合分子 |
| CN114085908B (zh) * | 2021-10-30 | 2023-08-08 | 中国人民解放军陆军军医大学第一附属医院 | 用于评估胶质母细胞瘤治疗效果的基因靶点组合及其应用 |
| AU2024282654A1 (en) | 2023-05-30 | 2025-12-04 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4256833A (en) | 1979-01-08 | 1981-03-17 | Majid Ali | Enzyme immunoassay for allergic disorders |
| US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
| FI891226A7 (fi) | 1988-04-28 | 1989-10-29 | The Board Of Trustees Of The Leland | Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
| RO110397B1 (ro) | 1989-03-21 | 1996-01-30 | Immune Response Corp San Diego | Vaccin pentru prevenirea sau tratarea unor boli care rezulta din raspunsuri patogene, prin populatii de celule t specifice, procedeu de obtinere si metode de diagnostic si tratament cu acesta |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| AU652540B2 (en) | 1989-07-19 | 1994-09-01 | Xoma Corporation | T cell receptor peptides as therapeutics for autoimmune and malignant disease |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | 二特異的免疫アドヘジン |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| WO1997033551A2 (en) | 1996-03-15 | 1997-09-18 | Millennium Pharmaceuticals | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
| CN1763097B (zh) | 1999-01-15 | 2011-04-13 | 杰南技术公司 | 具有改变的效应功能的多肽变体 |
| CN1437478A (zh) | 2000-04-25 | 2003-08-20 | Idec药物公司 | 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1667669A2 (en) * | 2003-05-30 | 2006-06-14 | Molecular Staging, Inc. | Inflammatory bowel diseases |
| US20110152115A1 (en) * | 2003-09-03 | 2011-06-23 | The United States of America, as represented by the Secretary, Department of Health and | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| MX337423B (es) | 2004-09-03 | 2016-03-04 | Genentech Inc | Antagonistas anti-beta7 humanizados y usos para los mismos. |
| US8030003B2 (en) * | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| WO2007067912A2 (en) * | 2005-12-07 | 2007-06-14 | Boehringer Ingelheim International Gmbh | Treatment and diagnostics of inflammatory diseases |
| BRPI0713000A8 (pt) * | 2006-06-12 | 2017-12-05 | Trubion Pharmaceuticals Inc | Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples |
| WO2008028031A2 (en) * | 2006-08-30 | 2008-03-06 | Centocor, Inc. | Markers and methods for assessing and treating ulcerative colitis and related disorders using a 43 gene panel |
| MX2009007368A (es) * | 2007-01-16 | 2009-07-16 | Wyeth Corp | Deteccion, tratamiento y monitoreo de la inflamacion, por medio del receptor de disparo expresado en la celula 1 mieloide (trem-1). |
| NZ597915A (en) * | 2007-02-28 | 2013-08-30 | Merck Sharp & Dohme | Combination therapy for treatment of immune disorders |
| TW200848431A (en) * | 2007-06-12 | 2008-12-16 | Trubion Pharmaceuticals Inc | Single-chain multivalent binding proteins with effector function |
| US9068230B2 (en) * | 2007-11-07 | 2015-06-30 | Genentech, Inc. | Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies |
| US20110177502A1 (en) * | 2008-02-19 | 2011-07-21 | Hakon Hakonarson | Identification of pediatric onset inflammatory disease loci and methods of use thereof for the diagnosis and treatment of the same |
| WO2009120877A2 (en) * | 2008-03-26 | 2009-10-01 | The Johns Hopkins University | Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases |
| BRPI0908665A2 (pt) * | 2008-05-16 | 2020-08-18 | Genentech Inc | método para a determinação da eficácia de um antagonista de integrina beta7 para o tratamento de um distúrbio inflamatório gastrointestinal, método de predição da responsividade de um paciente, método para a determinaçao da dosagem de um antagonista de integrina beta7, método para determinaçao do regime terapêutico de um antagonista de integrina beta7, método para predição de prognóstico de uma doença inflamatória intestinal, método de elaboração de um tratamento e método de identificação de uma população de linfócitos |
| EP2347256A4 (en) * | 2008-10-09 | 2012-02-08 | Alfagene Bioscience Inc | USE AND IDENTIFY BIOMARKERS FOR STOMACH DISEASES |
| JP2012507723A (ja) * | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| AU2010236568B2 (en) * | 2009-04-14 | 2015-08-27 | Société des Produits Nestlé S.A. | Inflammatory bowel disease prognostics |
| CN102639710A (zh) * | 2009-07-20 | 2012-08-15 | 基因泰克公司 | 克罗恩病的基因表达标记 |
| TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| US8766034B2 (en) * | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
| EP2668287B1 (en) * | 2011-01-25 | 2017-09-06 | TC LAND Expression | Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from rheumatoid arthritis to tnf-alpha blocking monoclonal antibody |
| MX2013011130A (es) * | 2011-03-31 | 2013-10-30 | Genentech Inc | Metodos de administracion de antagonistas de integrina beta7. |
| US20130040835A1 (en) * | 2011-05-05 | 2013-02-14 | Exagen Diagnostics, Inc | Genes predictive of anti-TNF response in inflammatory diseases |
| CN102876794B (zh) * | 2012-09-29 | 2014-07-02 | 山东省皮肤病性病防治研究所 | 单核苷酸多态性rs6871626在检测麻风病易感基因中的应用 |
| CN102876793B (zh) * | 2012-09-29 | 2014-03-12 | 山东省皮肤病性病防治研究所 | 单核苷酸多态性rs2058660在检测麻风病易感基因中的应用 |
| AU2013326921C1 (en) | 2012-10-05 | 2018-01-18 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
| RU2015145610A (ru) | 2013-03-27 | 2017-05-04 | Дженентек, Инк. | Применение биомаркеров для оценки лечения желудочно-кишечных воспалительных расстройств антагонистами бета7 интегрина |
| CN106102767B (zh) | 2014-03-27 | 2021-08-10 | 豪夫迈·罗氏有限公司 | 用于诊断和治疗炎症性肠病的方法 |
-
2015
- 2015-03-26 CN CN201580016240.3A patent/CN106102767B/zh not_active Expired - Fee Related
- 2015-03-26 CN CN202110901698.4A patent/CN113604543A/zh active Pending
- 2015-03-26 EP EP15768557.9A patent/EP3122377A4/en not_active Withdrawn
- 2015-03-26 KR KR1020227015554A patent/KR20220065091A/ko not_active Ceased
- 2015-03-26 MA MA039804A patent/MA39804A/fr unknown
- 2015-03-26 KR KR1020167026095A patent/KR102397324B1/ko active Active
- 2015-03-26 AU AU2015235986A patent/AU2015235986B2/en not_active Ceased
- 2015-03-26 BR BR112016020053-5A patent/BR112016020053A2/pt not_active Application Discontinuation
- 2015-03-26 WO PCT/US2015/022762 patent/WO2015148809A1/en not_active Ceased
- 2015-03-26 CA CA2939246A patent/CA2939246A1/en active Pending
- 2015-03-26 RU RU2016136716A patent/RU2016136716A/ru not_active Application Discontinuation
- 2015-03-26 SG SG11201607938UA patent/SG11201607938UA/en unknown
- 2015-03-26 MX MX2016012282A patent/MX2016012282A/es unknown
- 2015-03-26 AR ARP150100901A patent/AR099856A1/es unknown
- 2015-03-26 JP JP2016559188A patent/JP7054990B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-14 IL IL247266A patent/IL247266B/en active IP Right Grant
- 2016-09-21 US US15/271,687 patent/US10273542B2/en active Active
- 2016-09-22 MX MX2022010809A patent/MX2022010809A/es unknown
-
2019
- 2019-03-07 US US16/295,536 patent/US10669587B2/en not_active Expired - Fee Related
- 2019-11-21 JP JP2019210883A patent/JP2020062013A/ja not_active Withdrawn
-
2020
- 2020-04-10 US US16/845,575 patent/US11261493B2/en active Active
- 2020-08-05 IL IL276516A patent/IL276516A/en unknown
-
2021
- 2021-01-28 AU AU2021200518A patent/AU2021200518B2/en not_active Ceased
- 2021-05-21 AU AU2021203296A patent/AU2021203296A1/en not_active Abandoned
- 2021-11-12 JP JP2021185176A patent/JP2022043033A/ja active Pending
-
2022
- 2022-01-20 US US17/580,357 patent/US20220186314A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099856A1 (es) | Métodos para diagnosticar y tratar la enfermedad de intestino inflamado | |
| CY1125190T1 (el) | Χρηση ομαδων γονιδιων fgfr μεταλλαγματων στην εξακριβωση του εαν καρκινοπαθεις θα αποκρινονται σε αγωγη me fgfr αναστολεα | |
| MX2020001156A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| AR095363A1 (es) | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 | |
| AR098155A1 (es) | Métodos para diagnosticar y tratar trastornos eosinofílicos | |
| BR112015023120A2 (pt) | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado | |
| AR103935A1 (es) | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2 | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| CY1114993T1 (el) | Προφιλ εκφρασης γονιδιου για να προβλεπονται εκβασεις καρκινου μαστου | |
| JOP20190280A1 (ar) | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية | |
| MX2017010569A (es) | Dispositivo, plataforma y ensayo para evaluacion de celulas. | |
| WO2018007872A9 (en) | Biomarkers for inflammatory bowel disease | |
| MX378733B (es) | Métodos in vitro y composiciones para identificar y usarse en el tratamiento de lupus. | |
| MX2022005159A (es) | Uso de biomarcadores para predecir la sensibilidad clinica a 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin- 5-il)metil)-2,2-difluoroacetamida. | |
| JP2017503481A5 (enExample) | ||
| AR080361A1 (es) | Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk) | |
| BR112015008042A2 (pt) | diagnósticos complementares para terapia com inibidor de quinase da família tec | |
| WO2015070191A3 (en) | Systems and methods for detection of genomic variants | |
| ES2863274T3 (es) | Biomarcador de muerte celular | |
| Alonso‐Dominguez et al. | PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase | |
| MX2025004135A (es) | Predictor de radioterapia de receptor de peptido usando un ensayo de expresion genica | |
| ES2721477T3 (es) | Materiales y métodos para evaluar la progresión del cáncer de próstata | |
| WO2019089858A3 (en) | Methods of assessing or monitoring a response to a cell therapy | |
| AR099950A1 (es) | Determinación de polimorfismos de un solo nucleótido de utilidad para la predicción de la respuesta a la rasagilina | |
| WO2020123880A3 (en) | Genomic rearrangements associated with prostate cancer and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |